GSA Capital Partners LLP Invests $88,000 in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

GSA Capital Partners LLP purchased a new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,204 shares of the company’s stock, valued at approximately $88,000. GSA Capital Partners LLP owned approximately 0.09% of ALX Oncology at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in ALX Oncology by 4.3% in the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after acquiring an additional 64,055 shares in the last quarter. CANADA LIFE ASSURANCE Co bought a new position in shares of ALX Oncology in the first quarter worth $27,000. EntryPoint Capital LLC acquired a new position in ALX Oncology in the first quarter valued at about $32,000. California State Teachers Retirement System lifted its position in ALX Oncology by 413.8% during the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock worth $254,000 after purchasing an additional 18,360 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in ALX Oncology by 31.6% during the second quarter. Bank of New York Mellon Corp now owns 104,966 shares of the company’s stock worth $633,000 after buying an additional 25,199 shares in the last quarter. 97.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ALXO shares. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, UBS Group decreased their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.50.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.47 on Tuesday. The stock has a 50-day moving average price of $1.59 and a two-hundred day moving average price of $4.77. ALX Oncology Holdings Inc. has a 12 month low of $1.19 and a 12 month high of $17.83. The company has a market capitalization of $77.53 million, a PE ratio of -0.49 and a beta of 1.03. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.